Taro Asaga

766 total citations
13 papers, 560 citations indexed

About

Taro Asaga is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Taro Asaga has authored 13 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Cancer Research and 2 papers in Surgery. Recurrent topics in Taro Asaga's work include Breast Cancer Treatment Studies (8 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer Treatment and Pharmacology (7 papers). Taro Asaga is often cited by papers focused on Breast Cancer Treatment Studies (8 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer Treatment and Pharmacology (7 papers). Taro Asaga collaborates with scholars based in Japan and United States. Taro Asaga's co-authors include Kenjiro Aogi, Yasuo Ohashi, Hironobu Minami, Shigemitsu Takashima, Seigo Nakamura, Yuichi Iino, Carsten Goessl, Toru Watanabe, Norio Kohno and Masakazu Toi and has published in prestigious journals such as Journal of Clinical Oncology, Oncology Reports and Japanese Journal of Clinical Oncology.

In The Last Decade

Taro Asaga

13 papers receiving 546 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Taro Asaga Japan	6	517	181	145	99	91	13	560
S. Jagdev United Kingdom	6	406 0.8×	192 1.1×	71 0.5×	62 0.6×	152 1.7×	8	469
Monica Zuradelli Italy	11	186 0.4×	47 0.3×	34 0.2×	14 0.1×	87 1.0×	34	378
Paul Cheng United States	7	402 0.8×	41 0.2×	42 0.3×	90 0.9×	23 0.3×	11	486
C. Caroti Italy	9	330 0.6×	23 0.1×	32 0.2×	17 0.2×	72 0.8×	21	419
Loretta D’Onofrio Italy	8	137 0.3×	51 0.3×	35 0.2×	11 0.1×	80 0.9×	18	299
Bertrand Filleul Belgium	8	69 0.1×	36 0.2×	33 0.2×	17 0.2×	84 0.9×	14	265
Aaron G. Margulies United States	5	167 0.3×	34 0.2×	164 1.1×	8 0.1×	22 0.2×	7	357
Richard H. Bromer United States	9	299 0.6×	33 0.2×	231 1.6×	4 0.0×	168 1.8×	14	552
Satinder Jagdev United Kingdom	11	244 0.5×	45 0.2×	343 2.4×	5 0.1×	248 2.7×	24	569
Michela Ceccolini Italy	11	441 0.9×	43 0.2×	33 0.2×	39 0.4×	23 0.3×	21	734

Countries citing papers authored by Taro Asaga

Since Specialization

Citations

This map shows the geographic impact of Taro Asaga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Taro Asaga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Taro Asaga more than expected).

Fields of papers citing papers by Taro Asaga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Taro Asaga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Taro Asaga. The network helps show where Taro Asaga may publish in the future.

Co-authorship network of co-authors of Taro Asaga

This figure shows the co-authorship network connecting the top 25 collaborators of Taro Asaga. A scholar is included among the top collaborators of Taro Asaga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Taro Asaga. Taro Asaga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Sano, Muneaki, Toshio Tabei, Kimito Suemasu, et al.. (2006). [Multicenter phase II trial of thrice-weekly docetaxel and weekly trastuzumab as preoperative chemotherapy in patients with HER 2-overexpressing breast cancer--Japan East Cancer Center Breast Cancer Consortium (JECBC) 02 Trial].. PubMed. 33(10). 1411–5. 4 indexed citations

Sato, Nobuaki, Muneaki Sano, Toshio Tabei, et al.. (2006). Combination docetaxel and trastuzumab treatment for patients with her-2-overexpressing metastatic breast cancer: A multicenter, phase-II study. Breast Cancer. 13(2). 166–171. 16 indexed citations

Saeki, Toshiaki, Tadashi Nomizu, Masakazu Toi, et al.. (2006). Dofequidar Fumarate (MS-209) in Combination With Cyclophosphamide, Doxorubicin, and Fluorouracil for Patients With Advanced or Recurrent Breast Cancer. Journal of Clinical Oncology. 25(4). 411–417. 59 indexed citations

Asaga, Taro, et al.. (2005). Sentinel lymphoscintigraphy in patients with breast cancer undergoing excisional biopsy. Annals of Nuclear Medicine. 19(8). 671–675. 9 indexed citations

Toi, Masakazu, Toshiaki Saeki, Kenjiro Aogi, et al.. (2005). Late Phase II Clinical Study of Vinorelbine Monotherapy in Advanced or Recurrent Breast Cancer Previously Treated with Anthracyclines and Taxanes. Japanese Journal of Clinical Oncology. 35(6). 310–315. 29 indexed citations

Kimura, Morihiko, Muneaki Sano, Toshio Tabei, et al.. (2005). [Study of three-weekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients].. PubMed. 32(3). 335–9. 1 indexed citations

Kohno, Norio, Kenjiro Aogi, Hironobu Minami, et al.. (2005). Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial. Journal of Clinical Oncology. 23(15). 3314–3321. 408 indexed citations

Ishikawa, Takashi, Satoru Shimizu, Masaaki Inaba, et al.. (2004). A Multicenter Phase II Study of Docetaxel 60 mg/m2 as First-Line Chemotherapy in Patients with Advanced or Recurrent Breast Cancer. Breast Cancer. 11(4). 374–379. 5 indexed citations

Nishimura, Reiki, Takeshi Tominaga, Shoshu Mitsuyama, et al.. (2004). Combination chemotherapy with docetaxel and doxifluridine showed a beneficial outcome in advanced or recurrent breast cancer patients with longer disease-free interval.. PubMed. 24(3b). 2085–91. 2 indexed citations

10.

Tominaga, Takeshi, Morihiko Kimura, Taro Asaga, et al.. (2004). 1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: A randomized controlled trial. Oncology Reports. 12(4). 797–803. 2 indexed citations

11.

Yoshida, Akira, Yoshiyasu Nakamura, Akio Shimizu, et al.. (2000). Significance of the parathyroid hormone-related protein expression in breast carcinoma. Breast Cancer. 7(3). 215–220. 20 indexed citations

12.

Abe, Masao, Osamu Kobayashi, Taro Asaga, et al.. (1986). A CASE OF GASTRIC CANCER WITH REMARKABLE CALCIFICATION AND A REVIEW OF 31 CASES IN THE JAPANESE LITERATURE. The journal of the Japanese Practical Surgeon Society. 47(6). 764–769. 1 indexed citations

13.

Asaga, Taro, et al.. (1983). Difference in polynucleation of cultured cells from human mammary tumors and normal mammary glands on treatment with cytochalasin B.. PubMed. 74(1). 95–9. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact